Ignite Creation Date:
2024-05-06 @ 12:36 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03802344
Status:
COMPLETED
Last Update Posted:
2020-12-16
First Post:
2019-01-10
Brief Title:
This Trial is a Randomised Multicentre Investigator-blind Vehicle and Comparator-controlled Parallel-group Trial With the Purpose of Evaluation Efficacy Safety and Convenience of the MC2-01 Cream
Sponsor:
MC2 Therapeutics
Organization:
MC2 Therapeutics
Study Overview
Official Title:
A Randomised Multicentre Investigator-Blind Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a randomized investigator-blind multicentre vehicle- and comparator-controlled parallel-group trial with the purpose of evaluating the efficacy safety and convenience of the MC2-01 cream
Detailed Description:
The MC2-01 Cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines In this trial the MC2-01 cream will be compared to a marketed product CALBDP combination and vehicle The purpose of the trial is to compare the clinical efficacy safety and convenience of this cream to the marketed product The trial will include a 8-week treatment period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None